← Back to Search

Other

BMS-986165 and cyclosporine for Psoriasis

Phase 1
Waitlist Available
Research Sponsored by Bristol-Myers Squibb
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
Approved for 20 Other Conditions
No Placebo-Only Group

Summary

This is an investigational study of Cyclosporine on the experimental medication BMS-986165 in healthy male participants.

Eligible Conditions
  • Psoriasis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

Approved for 20 Other Conditions
This treatment demonstrated efficacy for 20 other conditions.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: BMS-986165 and cyclosporineExperimental Treatment2 Interventions
BMS-986165 and cyclosporine administered orally
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Deucravacitinib
Not yet FDA approved
Cyclosporine
FDA approved

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Bristol-Myers SquibbLead Sponsor
2,682 Previous Clinical Trials
4,124,967 Total Patients Enrolled
37 Trials studying Psoriasis
20,171 Patients Enrolled for Psoriasis
~7 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top